Palatin Technologies PTN 深 沪
已收盘 09-20 16:00:00 美东时间
1.28
-0.010
-0.78%
华盛通- 最 高1.34
- 今 开1.31
- 成交量 47.05万股
- 最 低 1.22
- 昨 收 1.29
- 总市值 1529.16万
- 52周最高 5.65
- 市盈率 静 --
- 换手率 3.94%
- 52周最低 1.22
- 委 比 33.33%
- 总股本 1194.66万
- 历史最高 44.50
- 量 比 2.58
- 振 幅 9.30%
- 历史最低 1.22
- 每 手 1
- 风险率 0.76%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones
Dry Eye Disease (DED): PL9643 MELODY-2 & MELODY-3 Phase 3 Pivotal Clinical Studies FDA Confirms Protocols and Endpoints Targeting Enrollment Start in 4Q Calendar Year 2024 Topline Results An...
09-09 19:30
Palatin stock climbs 8% on Phase 3 testing update for PL9643
Palatin Technologies (NYSE:PTN) stock was up 8% in afternoon trading after the company announced the FDA has confirmed the acceptability of the protocols and endpoints for the remaining Phase 3 clinic...
08-29 03:21
HC Wainwright & Co. Reiterates Buy on Palatin Techs, Maintains $17 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Palatin Techs (AMEX:PTN) with a Buy and maintains $17 price target.
08-22 21:53
快讯 | Palatin的Bremelanotide与Tirzepatide（GLP-1）联合治疗肥胖的2期临床研究中首名患者接受了药物注射。
First Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Adm...
08-22 19:30
快讯 | Palatin Technologies Inc - 预计在2025年第一季度日历年发布最新业绩
Palatin Technologies Inc - Topline Results Expected in 1Q Calendar Year 2025
08-22 19:30
快讯 | Palatin Technologies公司：预计在2024年第三季度完成招募。
Palatin Technologies Inc: Complete Enrollment Currently Expected in 3Q 2024
08-22 19:30
复星医药： 在创新研发推进过程中，公司持续动态评估管线的市场价值
证券之星消息，复星医药(600196)08月21日在投资者关系平台上答复投资者关心的问题。 投资者：请介绍一下从Palatin公司授权的“女伟哥”bremel...
08-21 19:01
Palatin Technologies Secures Growth with Warrant Exercise Deal
Palatin Technologies (PTN) has provided an update. In a strategic move to bolst...
06-21 20:58
Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds
CRANBURY, N.J., June 21, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines ba...
06-21 20:00
快讯 | palatin technologies: 可能于2025年上半年开始进行III期临床研究，针对Pde5I单药治疗无反应的ED患者。
Palatin Technologies: Potential Phase 3 Clinical Study in Ed Patients Who Do No...
06-20 19:31
